Evidence map›Paper›PMID 26036358›Full record

ArticlePigment cell & melanoma research2015

Expression of oncogenic BRAFV600E in melanocytes induces Schwannian differentiation in vivo.

Chi Luo, Jodie R Pietruska, Jinghao Sheng, Roderick T Bronson, Miaofen G Hu, Rutao Cui, Philip W Hinds

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Pigment cell & melanoma research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. EGR3 Inhibits Tumor Progression by Inducing Schwann Cell-Like Differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  2. Article
  3. Article
  4. Classification and Grading of Melanocytic Lesions in a Mouse Model ofThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chi LuoGraduate Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA.
Jodie R PietruskaMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA, USA.
Jinghao ShengMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA, USA.
Roderick T BronsonRodent Histopathology Core, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
Miaofen G HuMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA, USA.
Rutao CuiDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Philip W HindsGraduate Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA.

Funding

Genetics of RAS, PTEN, BRAF and CDKN2A in MelanomaR01CA095798 · NCI · TUFTS MEDICAL CENTER · PI HINDS, PHILIP W. · 2005 to 2009
$1.4M
NCI NIH HHS CA095798NCI NIH HHS R01 CA095798
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell DifferentiationMutationAnimalsCell LineageCrosses, GeneticHumansKi-67 AntigenMelaninsMelanocytesMiceMice, Inbred C57BLMice, TransgenicNeural CrestPhenotypePigmentationProto-Oncogene Proteins B-rafBRAF protein, humanKi-67 AntigenMelaninsProto-Oncogene Proteins B-raf

Identifiers

PMID26036358
PMCPMC4539285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.